1800-272-662
Shopping Cart 0
countryflagAU
Login

Noxopharm Ltd

Healthcare AU NOX

0.061AUD
0.002(3.39%)

Last update at 2026-03-13T04:53:00Z

Day Range

0.060.06
LowHigh

52 Week Range

0.040.14
LowHigh

Fundamentals

  • Previous Close 0.06
  • Market Cap18.13M
  • Volume31942
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.41383M
  • Revenue TTM3.40M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM -0.95007M
  • Diluted EPS TTM-0.02

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -4.88417M -5.97839M -15.05637M -18.66681M -9.34675M
Minority interest - - - - -
Net income -4.88417M -3.57812M -15.05637M -18.74414M -24.44703M
Selling general administrative 0.92M 1.04M 4.88M 6.58M 5.69M
Selling and marketing expenses 0.02M 0.06M 0.19M 0.10M 0.13M
Gross profit -1.44565M -0.53481M - - -
Reconciled depreciation - 0.00174M 0.15M 0.26M 0.26M
Ebit -5.38657M -5.94723M -14.95544M -18.58948M -7.16053M
Ebitda -5.38483M -5.94549M -14.80091M -18.32796M -6.89881M
Depreciation and amortization 0.00174M 0.00174M 0.15M 0.26M 0.26M
Non operating income net other - - - - -
Operating income -9.65131M -7.53500M -14.95544M -18.58948M -7.16053M
Other operating expenses 12.47M 9.94M 16.60M 15.21M 20.21M
Interest expense 0.50M 0.03M 0.04M 0.08M 2.19M
Tax provision - 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.49M 0.00693M 4.49M 0.05M 5.06M
Net interest income - -0.02423M 0.04M -0.03039M -2.04675M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -2.82083M -2.40028M 1.60M 0.08M 15.10M
Total revenue 2.82M 2.40M 6.07M 5.45M 5.75M
Total operating expenses 8.21M 7.00M 16.60M 15.21M 20.21M
Cost of revenue 4.27M 2.94M - - -
Total other income expense net 4.77M 1.56M 1.50M -0.07734M -2.18622M
Discontinued operations - - - - -
Net income from continuing ops - -3.57812M -15.05637M -18.66681M -9.34675M
Net income applicable to common shares -4.88417M -3.57812M -15.05637M -18.66681M -9.34675M
Preferred stock and other adjustments - - - - -
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 4.58M 6.78M 10.13M 26.59M 47.85M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 0.08M 0.04M 0.00000M 0.46M 0.07M
Total liab 3.89M 1.29M 1.06M 2.48M 7.08M
Total stockholder equity 0.69M 5.50M 9.07M 24.12M 40.78M
Deferred long term liab - - - - -
Other current liab 0.94M 0.60M 0.51M 1.31M 0.45M
Common stock 74.64M 74.64M 74.64M 74.64M 72.62M
Capital stock - - 74.64M 74.64M 72.62M
Retained earnings -74.64582M -70.07034M -72.06052M -58.80303M -40.33330M
Other liab - - 0.09M 0.19M 0.15M
Good will - - - - -
Other assets - - 0.00000M 0.12M 0.12M
Cash 1.55M 2.32M 3.01M 14.01M 26.80M
Cash and equivalents - - 0.00000M 8.00M 10.00M
Total current liabilities 3.87M 1.25M 0.96M 2.28M 6.81M
Current deferred revenue - - - - -
Net debt 0.92M -2.31993M -3.00867M -13.85004M -26.44648M
Short term debt 2.48M - 0.00000M 0.16M 0.23M
Short long term debt - - - - -
Short long term debt total 2.48M - - 0.16M 0.35M
Other stockholder equity - - 6.50M 8.29M 8.49M
Property plant equipment - - 0.00741M 0.22M 0.48M
Total current assets 4.58M 4.77M 9.16M 20.83M 32.97M
Long term investments - - 0.96M 5.42M 14.27M
Net tangible assets - - 9.07M 24.12M 40.78M
Short term investments - - - - -
Net receivables 2.95M 2.40M 6.08M 5.21M 5.80M
Long term debt - - - - -
Inventory - - - 1.15M 0.31M
Accounts payable 0.45M 0.65M 0.45M 0.81M 6.13M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.70M 0.93M 6.50M 8.29M 8.49M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - - 0.12M 0.12M
Deferred long term asset charges - - - - -
Non current assets total 0.00392M 2.02M 0.97M 5.76M 14.88M
Capital lease obligations - - - 0.16M 0.35M
Long term debt total - - 0.00000M 0.00000M 0.12M
Breakdown 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly yearly
Date 2025-06-30 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments - - 0.12M - 0.23M
Change to liabilities - - -1.07874M -4.33445M 4.34M
Total cashflows from investing activities 2.48M 0.00000M 0.12M 0.12M 0.23M
Net borrowings - 2.00M -0.17810M -0.22914M -0.24482M
Total cash from financing activities 2.60M 0.00000M -0.17810M 0.98M 28.32M
Change to operating activities - - -0.18126M -0.07839M 0.19M
Net income -4.88417M -3.57812M -15.05637M -18.74414M -11.53297M
Change in cash -0.76575M -0.68875M -11.00199M -12.78512M 19.70M
Begin period cash flow 2.32M 3.01M 14.01M 26.80M 7.10M
End period cash flow 1.55M 2.32M 3.01M 14.01M 26.80M
Total cash from operating activities -5.82460M -0.68431M -10.94635M -18.48263M -8.85044M
Issuance of capital stock - - - 1.20M 30.10M
Depreciation 0.00174M 0.00174M 0.15M 0.26M 0.26M
Other cashflows from investing activities 2.48M 0.00000M 0.12M 0.12M 0.23M
Dividends paid - - - - -
Change to inventory - - 1.15M -0.83498M 0.21M
Change to account receivables -0.57497M 3.70M -0.47743M 0.18M -1.13977M
Sale purchase of stock - - 0.00000M 1.20M -1.52835M
Other cashflows from financing activities - -2.00000M -0.17810M -0.22914M -0.24482M
Change to netincome - - 4.55M 9.74M -3.36711M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.45131M 3.73M 5.12M 5.95M 4.76M
Stock based compensation 0.06M - - - -
Other non cash items -0.55486M -0.84093M - 18.48M 9.09M
Free cash flow -5.82460M -0.68431M -10.94635M -18.48263M -8.85044M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
NOX
Noxopharm Ltd		 0.002 3.39% 0.06 - - 5.34 30.28 -1.1582
CSL
CSL Ltd		 -0.01 0.0071% 141.03 16.27 19.23 4.44 2.61 3.90 11.73
TLX
TELIX Pharmaceuticals Ltd		 0.06 0.53% 11.29 - 1111.11 4.73 6.52 3.77 86.30
MSB
Mesoblast Ltd		 -0.03 1.40% 2.11 - 454.55 41.58 3.42 30.11 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.19 1.59% 11.76 51.13 44.25 23.04 4.47 18.83 55.27

Reports Covered

Stock Research & News

View All

Profile

Noxopharm Limited, a biotech company, engages in the discovering and developing treatments for cancer and inflammation, and mRNA vaccines in Australia. It develops Sofra, a platform that focuses on the development of immunomodulators for mRNA vaccines and mRNA therapeutics, as well as for the treatment of autoimmune diseases; and Chroma technology platform to develop CRO-67 dual-cell therapy drug for the treatment of pancreatic cancer and various molecules for the treatment of autoimmune disease and hyperinflammatory conditions. The company also develops orphan drug designations to treat less common disease; and IONIC program with Veyonda, which is combined with the Bristol Myers Squibb checkpoint inhibitor Opdivo for the treatment of various solid tumor types. The company was incorporated in 2015 and is based in Glenhaven, Australia.

Noxopharm Ltd

60 Linksley Avenue, Glenhaven, NSW, Australia, 2156

Key Executives

Name Title Year Born
Dr. Gisela Mautner CEO, Exec. MD, Chief Medical Officer & Director NA
Mr. Shawn Van Boheemen Chief Financial Officer NA
Ms. Jeanette Bell Ph.D. Chief Operating Officer NA
Dr. John Wilkinson B.Sc., Ph.D. Chief Scientific Officer of Oncology NA
Dr. Olivier Laczka B.S., M.Sc., Ph.D. Chief Scientific Officer of Inflammation NA
Mr. David James Franks B.Ec, BEc, C.A., CA, F Fin, J.P., JP. Company Sec. 1970
Dr. Gisela Mautner CEO, Executive MD & Director NA
Mr. Shawn Van Boheemen FCPA Chief Financial Officer NA
Mr. David James Franks BEc, C.A., F Fin, J.P. Company Secretary 1970
Dr. Gisela Mautner CEO, Executive MD & Director NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.